enGene appoints Amy Pott as chief global commercialization officer

enGene (ENGN) announced the appointment of Amy Pott as chief global commercialization officer. In this role, Pott will serve as the company’s first dedicated executive for commercialization planning and execution, reporting to enGene’s CEO, Ron Cooper. This appointment marks a significant milestone, as the company expects to file a biologics license application with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guerin-unresponsive, non-muscle invasive bladder cancer, following the completion of the pivotal cohort of the LEGEND trial. Pott joins enGene from Astellas Pharma (ALPMY), where she most recently served as senior VP, strategic brand marketing, ophthalmics and rare diseases, and previously as head of commercial, gene therapies.